


Revance Therapeutics (Fri, May 03, 2024)

Sell candidate since Mar 13, 2024

Loss -34.39%

StockInvest.us
Gyneju st. 14, "ROCKIT"
Vilnius, LT-01109
Lithuania



score: **-1.81**

#13611/ 30045

Trend: Sell
MV Long: Sell
MV Short: Buy
Pivot: Buy
Volume: Buy
MACD: Buy

Tech commentaries:

The **Revance Therapeutics** stock price gained **4.77%** on the last trading day (Friday, 3rd May 2024), rising from **\$3.77** to **\$3.95**. During the last trading day the stock fluctuated **4.90%** from a day low at **\$3.88** to a day high of **\$4.07**. The price has been going up and down for this period, and there has been a 4.5% gain for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, **118 thousand** more shares were traded than the day before. In total, 1 million shares were bought and sold for approximately **\$5.37** million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall **-33.56%** during the next 3 months and, with a 90% probability hold a price between **\$2.02** and **\$3.47** at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

A buy signal was issued from a pivot bottom point on **Thursday, April 25, 2024**, and so far it has risen 20.06%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The **Revance Therapeutics** stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at **\$4.28**. On a fall, the stock will find some support from the short-term average at **\$3.64**. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal.

Revance Therapeutics finds support from accumulated volume at **\$3.81** and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance just above today's level from accumulated volume at **\$3.97**, **\$4.41** and **\$4.69**.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved **\$0.190** between high and low, or **4.90%**. For the last week, the stock has had daily average volatility of **8.69%**.

Revance Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Risk: High

Evaluation: Sell Candidate

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.